Screening the RFX6-DNA binding domain for potential genetic variants in patients with type 2 diabetes

Table 1 Demographic and clinical characteristics of diabetic patients and healthy controls

	Control group	Diabetic patients	P-value
Primary screening, (n = 98)
Male, n (%)	32 (65%)	24 (49%)	0.285
Age (mean ± SD)	50.1 ± 12.3	54.7 ± 10.7	0.149
Female, n (%)	17 (35%)	25 (51%)	0.217
Age (mean ± SD)	47.7 ± 15.5	56.2 ± 13.2	0.065
FBG (mg/dL)	97± 10	192± 94	< 0.001
HbA1c (%)	5.4± 0.4	8.2± 2.2	< 0.001
Screening the IVS6+31 C>T, (n = 283)
Male, n (%)	78 (55%)	59 (42%)	0.105
Age (mean ± SD)	48.9 ± 15.2	57.4 ± 11.3	0.001
Female, n (%)	64 (45%)	82 (58%)	0.136
Age (mean ± SD)	51.8 ± 15.2	57.1 ± 11.5	0.024
FBG (mg/dL)	98± 10.4	177± 80	< 0.001
HbA1c (%)	5.4± 0.5	7.8± 1.9	< 0.001

P-value is significant at ≤ 0.05. FBG: Fasting blood glucose; HbA1c: Glycosylated haemoglobin.

Table 2 Primer sequences used in DNA amplification of DNA binding domain sequence of RFX6 gene

Primer	Sequence (5’-3’)	Ta (°C)	Size (bp)
RFX6-3	F: 5- CTT ATG TCT ACT CAT TAC CTC -3	50	306
	R: 5- TCA TGC TAT CTG CCT GAC -3
RFX6-4	F: 5- CAG TTC ATT CAG AGT TCA AC -3	56	216
	R: 5- CTT CAT GCA CAA GAG CAG -3
RFX6-5	F: 5- GTC ATC AGG GTT TGC AGT TC -3	50	258
	R: 5- ATT CAA TAG GTA TCA TGC -3
RFX6-6	F: 5- GTA AGT TGA GAA AGA TGC -3	56	258
	R: 5- CAT GTA TTG CTC AGC TTG -3

Ta indicates annealing temperature.

Table 3 Association between the variant IVS6+31 C>T investigated in RFX6 gene and type 2 diabetes risk

	Control, n (%)	T2D, n (%)	P-value	OR	95%CI
genotype
C \ C	130 (91.5)	128 (90.8)	0.97	0.9	0.39-2.06
C \ T	12 (8.5)	13 (9.2)		1.1	0.48-2.50
T \ T	0	0		1	0.02-51.1
Allele
C	272 (95.7)	269 ( 95.3)	0.82	0.9	0.41-2.03
T	12 (4.3)	13 (4.7)		1.1	0.49-2.44

P-value is significant at ≤ 0.05. OR: ODDs Ratio; CI: Confidence Interval; T2D: Type 2 diabetes.